Literature DB >> 26405327

Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir.

Dennis J Cada1, James Leonard2, Terri L Levien3, Danial E Baker4.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The May 2015 monograph topics are palbociclib, lenvatinib, nivolumab, ferric pyrophosphate citrate solution, and secukinumab. The Safety MUE is on non-opioid injectable pain or fever medications.

Entities:  

Year:  2015        PMID： 26405327      PMCID： PMC4567207          DOI： 10.1310/hpj5005-396

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  10 in total

1.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

2.  An interferon-free antiviral regimen for HCV after liver transplantation.

Authors:  Paul Y Kwo; Parvez S Mantry; Eoin Coakley; Helen S Te; Hugo E Vargas; Robert Brown; Fredric Gordon; Josh Levitsky; Norah A Terrault; James R Burton; Wangang Xie; Carolyn Setze; Prajakta Badri; Tami Pilot-Matias; Regis A Vilchez; Xavier Forns
Journal:  N Engl J Med       Date:  2014-11-11       Impact factor: 91.245

3.  ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.

Authors:  Pietro Andreone; Massimo G Colombo; Jeffrey V Enejosa; Iftihar Koksal; Peter Ferenci; Andreas Maieron; Beat Müllhaupt; Yves Horsmans; Ola Weiland; Henk W Reesink; Lino Rodrigues; Yiran B Hu; Thomas Podsadecki; Barry Bernstein
Journal:  Gastroenterology       Date:  2014-05-09       Impact factor: 22.682

4.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

6.  ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

Authors:  Fred Poordad; Christophe Hezode; Roger Trinh; Kris V Kowdley; Stefan Zeuzem; Kosh Agarwal; Mitchell L Shiffman; Heiner Wedemeyer; Thomas Berg; Eric M Yoshida; Xavier Forns; Sandra S Lovell; Barbara Da Silva-Tillmann; Christine A Collins; Andrew L Campbell; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

7.  Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.

Authors:  Eric Lawitz; Greg Sullivan; Maribel Rodriguez-Torres; Michael Bennett; Fred Poordad; Mudra Kapoor; Prajakta Badri; Andrew Campbell; Lino Rodrigues; Yiran Hu; Tami Pilot-Matias; Regis A Vilchez
Journal:  J Infect       Date:  2014-09-22       Impact factor: 6.072

8.  Safety and efficacy of ombitasvir - 450/r and dasabuvir and ribavirin in HCV/HIV-1 co-infected patients receiving atazanavir or raltegravir ART regimens.

Authors:  Joseph J Eron; Jay Lalezari; Jihad Slim; Joseph Gathe; Peter J Ruane; Chia Wang; Richard Elion; Gary Blick; Amit Khatri; Yiran B Hu; Krystal Gibbons; Linda Fredrick; Melannie Co; Ronald D'Amico; Barbara Da Silva-Tillmann; Roger Trinh; Mark S Sulkowski
Journal:  J Int AIDS Soc       Date:  2014-11-02       Impact factor: 5.396

9.  Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

Authors:  Kris V Kowdley; Eric Lawitz; Fred Poordad; Daniel E Cohen; David R Nelson; Stefan Zeuzem; Gregory T Everson; Paul Kwo; Graham R Foster; Mark S Sulkowski; Wangang Xie; Tami Pilot-Matias; George Liossis; Lois Larsen; Amit Khatri; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245
  10 in total
  1 in total

1.  Sulfur(vi) fluoride exchange as a key reaction for synthesizing biaryl sulfate core derivatives as potent hepatitis C virus NS5A inhibitors and their structure-activity relationship studies.

Authors:  Youngsu You; Hee Sun Kim; Jung Woo Park; Gyochang Keum; Sung Key Jang; B Moon Kim
Journal:  RSC Adv       Date:  2018-09-12       Impact factor: 4.036
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.